( Last Updated : January 19, 2022)
Generic Name:
Project Status:
Therapeutic Area:
Osteoporosis, postmenopausal women
Amgen Canada Inc.
Brand Name:
Project Line:
Reimbursement Review
Project Number:
NOC Status at Filing:
Post NOC


Manufacturer Requested Reimbursement Criteria1:
The treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture and who are at very high risk for future fracture.
Submission Type:
Fee Schedule:
Schedule A
The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open04-Jan-21
Call for patient/clinician input closed26-Feb-21

- Patient input submission received from Osteoporosis Canada

Submission received01-Feb-21
Submission accepted16-Feb-21
Review initiated25-Feb-21

- Submission temporarily suspended pending receipt of information

- Additional information has been received and the temporary suspension of the review has been lifted

Draft CADTH review report(s) provided to sponsor for comment29-Jul-21
Deadline for sponsors comments10-Aug-21
CADTH responses on draft review report(s) provided to sponsor10-Sep-21
Expert committee meeting (initial)22-Sep-21
Draft recommendation issued to sponsor05-Oct-21
Draft recommendation posted for stakeholder feedback14-Oct-21
End of feedback period28-Oct-21
Final recommendation issued to sponsor and drug plans11-Nov-21
Final recommendation posted29-Nov-21
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)25-Nov-21
CADTH review report(s) posted19-Jan-22